STREAMEX CORP. Deferred Income Tax Expense (Benefit)
STREAMEX CORP. (STEX) reported Deferred Income Tax Expense (Benefit) of -$1.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-14
- STREAMEX CORP. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$505.00K.
- STREAMEX CORP. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$565.00K.
- STREAMEX CORP. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$491.00K.
- STREAMEX CORP. deferred income tax expense (benefit) for fiscal 2025 was -$1.26M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$505.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.07M 10-Q · filed 2026-08-14 | -$1.56M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$565.00K 10-Q · filed 2026-05-14 | -$1.06M derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2025-12-31 | -$491.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.26M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | -$765.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B |